Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2014 Oct;14(10):1097-100. doi: 10.1586/14737140.2014.940329. Epub 2014 Jul 14.

Could valproic acid be an effective anticancer agent? The evidence so far.

Author information

1
Atlanta VAMC, Atlanta, GA, USA.

Abstract

Valproic acid is an inhibitor of class I histone deacetylases. Epigenetic therapies in cancer have been focus of a keen interest and histone deacetylase inhibitors, in particular, have been approved for certain types of hematologic malignancies. Valproic acid is an attractive candidate for cancer therapy due to its mechanism of action, its low cost and generally good clinical tolerability. In the following editorial, we will review its role as monotherapy for cancer, its place in combination epigenetic therapy, and its role as chemosensitizer, and cancer preventative agent.

KEYWORDS:

AML; HDAC; MDS; cancer prevention; methylation; valproic acid

PMID:
25017212
PMCID:
PMC4579528
DOI:
10.1586/14737140.2014.940329
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center